Journal article icon

Journal article

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia

Abstract:

PURPOSE: Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). Preclinical work suggested that addition of azacitidine to ivosidenib enhances mIDH1 inhibition–related differentiation and apoptosis.

PATIENTS AND METHODS: This was an open-label, multicenter, phase Ib trial comprising dose-finding and expansion stages to evaluate safety and ef...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Role:
Author
ORCID:
0000-0001-9003-0390
Expand authors...
Publisher:
American Society of Clinical Oncology Publisher's website
Journal:
Journal of Clinical Oncology Journal website
Volume:
39
Issue:
1
Pages:
57-65
Publication date:
2020-10-29
DOI:
EISSN:
1527-7755
ISSN:
0732-183X
Pmid:
33119479
Pubs id:
1140881
Local pid:
pubs:1140881
Language:
English
Keywords:
Format:
Print-Electronic

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP